Seres Therapeutics Company Profile (NASDAQ:MCRB)

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Seres Therapeutics, Inc. (NASDAQ:MCRB) released its earnings results on Thursday, August, 3rd. The company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by $0.10. The business earned $3 million during the quarter, compared to the consensus estimate of $3 million. Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 80.21%. The firm's revenue for the quarter was up .0% on a year-over-year basis. During the same period last year, the business posted ($0.70) EPS. View Seres Therapeutics' Earnings History.

Seres Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Seres Therapeutics.

5 brokerages have issued twelve-month price targets for Seres Therapeutics' stock. Their predictions range from $16.00 to $20.00. On average, they expect Seres Therapeutics' stock price to reach $18.25 in the next twelve months. View Analyst Ratings for Seres Therapeutics.

Here are some recent quotes from research analysts about Seres Therapeutics stock:

• 1. According to Zacks Investment Research, "Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (8/8/2017)
• 2. Cowen and Company analysts commented, "We are optimistic that modifications to the clinical trial plan for SER-109 in recurrent." (5/19/2017)
• 3. Canaccord Genuity analysts commented, "We believe that SER-109 Phase 2 trial study power was decreased by the inclusion of misdiagnosed and non-disease active patients. MCRB indicated that 72 of the 89 patients enrolled in the Phase 2 trials were chosen based on C. Difficile PCR diagnosis. A positive PCR test indicates that the cytotoxin gene is present, but does not directly indicate that the C. Difficile bacterium is producing the cytotoxin that causes the underlying symptoms. Thus a direct testing of cytotoxin is the most indicative of disease activity, and further qualifying stool samples analysis showed that only 15 of 31 PCR- positive samples were cytotoxin-positive. Importantly, Optimer utilized toxin testing for its fidaxomicin clinical program for recurrent C." (1/31/2017)

Some companies that are related to Seres Therapeutics include Sangamo Therapeutics (SGMO), Clinigen Group PLC (CLIN), Dynavax Technologies Corporation (DVAX), Dermira (DERM), Acorda Therapeutics (ACOR), Epizyme (EPZM), Xencor (XNCR), Athenex (ATNX), NeuroDerm (NDRM), Five Prime Therapeutics (FPRX), Ascendis Pharma A/S (ASND), Omeros Corporation (OMER), REGENXBIO (RGNX), Amarin Corporation PLC (AMRN), Retrophin (RTRX), Intra-Cellular Therapies (ITCI), ZIOPHARM Oncology (ZIOP) and PTC Therapeutics (PTCT).

Seres Therapeutics' management team includes the folowing people:

• Roger Pomerantz M.D., Chairman of the Board, President, Chief Executive Officer
• Eric D. Shaff, Chief Financial Officer, Executive Vice President
• John G. Aunins Ph.D., Chief Technology Officer, Executive Vice President - Bioprocess and Manufacturing
• David N. Cook Ph.D., Chief Scientific Officer, Executive Vice President - Research & Development
• Thomas J. DesRosier J.D., Chief Legal Officer, Executive Vice President and Secretary
• Michele Trucksis Ph.D. M.D., Chief Medical Officer and Executive Vice President
• Noubar B. Afeyan, Lead Independent Director
• Willard H. Dere M.D., Director
• Dennis A. Ausiello M.D., Independent Director
• Gregory Behar, Independent Director

(MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Seres Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Flagship Pioneering Inc. (31.40%), FMR LLC (14.99%), Vanguard Group Inc. (3.92%), Capital World Investors (3.85%), ARK Investment Management LLC (1.89%) and Federated Investors Inc. PA (1.85%). Company insiders that own Seres Therapeutics stock include David N Cook, Eric D Shaff, John G Aunins, Michele Trucksis, Roger Pomerantz and Ventures Fund 2007 L Flagship. View Institutional Ownership Trends for Seres Therapeutics.

Seres Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., TIAA CREF Investment Management LLC, Federated Investors Inc. PA, Tudor Investment Corp ET AL, Goldman Sachs Group Inc., Wells Fargo & Company MN, Cutler Group LP and PDT Partners LLC. View Insider Buying and Selling for Seres Therapeutics.

Seres Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, State Street Corp, Northern Trust Corp, DekaBank Deutsche Girozentrale, Citadel Advisors LLC, Vanguard Group Inc., State of Wisconsin Investment Board and Dimensional Fund Advisors LP. View Insider Buying and Selling for Seres Therapeutics.

Shares of Seres Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Seres Therapeutics stock can currently be purchased for approximately $16.09.